Removing fallopian tubes to lower risk of aggressive uterine cancer
Biologic rationale of fallopian tube removal to prevent uterine serous carcinoma
This project looks at whether removing the fallopian tubes can reduce the chance of a deadly form of uterine cancer in people at risk.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical University of South Carolina NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project ID | NIH-11110851 on NIH RePORTER |
What this research studies
This work uses a mouse model that develops uterine serous cancer from the fallopian tube to test whether removing the ovary and fallopian tube lowers cancer cell appearance in the uterus. Investigators will label and track individual cells in the mouse fallopian tube to see how and when cells move to the uterus. They will also compare the mouse findings to human genetic and tissue data to check whether the same patterns occur in people. The combined lab and bioinformatics approach aims to explain why tubal procedures might protect against aggressive uterine cancer.
Who could benefit from this research
Good fit: People at higher risk for uterine serous carcinoma—such as those with p53-related molecular changes, strong family history, or those planning gynecologic surgery—would be most directly affected.
Not a fit: People without risk factors for type II uterine cancer (for example those with the more common, estrogen-driven type I endometrial cancer) are unlikely to gain direct benefit from this work.
Why it matters
Potential benefit: If confirmed, this could support removing fallopian tubes as a way to prevent aggressive uterine serous cancer for people at increased risk.
How similar studies have performed: An observational human study previously suggested tubal ligation may reduce type II endometrial cancer rates, but experimental confirmation and biological mechanisms are still limited.
Where this research is happening
Charleston, United States
- Medical University of South Carolina — Charleston, United States (Active)
Researchers
- Principal investigator: Delaney, Joe R — Medical University of South Carolina
- Study coordinator: Delaney, Joe R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.